valve

SOLACI-SBHCI 2023 Scientific Coverage – Day 3

The third day of the Congress started at the Copacabana Arena with the International Live Case held at Nanjing First Hospital, Nanjing, China, which showcased a successful and illustrative step-by-step Transcatheter Coronary Intervention (TCI) angioplasty with circulatory support and optimized results using Intravascular Ultrasound (IVUS) applicability. Following that, Dr. Fei Ye presented Intravascular Imaging and<a href="https://solaci.org/en/2023/08/05/solaci-sbhci-2023-scientific-coverage-day-3/" title="Read more" >...</a>

SOLACI/SBHCI 2023: Scientific Coverage &#8211; Day 2

The second day of the SOLACI/SBHCI 2023 Congress, the largest interventional cardiology meeting in Latin America, organized by the Latin American Society of Interventional Cardiology (SOLACI) and the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI), held in Rio de Janeiro, featured various national and international guests, along with important sessions on the main topics<a href="https://solaci.org/en/2023/08/03/solaci-sbhci-2023-scientific-coverage-day-2/" title="Read more" >...</a>

Scientific Coverage SOLACI-SBHCI 2023

Congress SOLACI-SBHCI 2023 &#8211; Day 1 Summary

Today, the SOLACI SBHCI 2023 Congress, the largest interventional cardiology event in Latin America, organized by the Latin American Society of Interventional Cardiology (SOLACI) and the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI), began in Rio de Janeiro. The event is taking place between August 2nd August 4th at the Windsor Convention Center &amp;<a href="https://solaci.org/en/2023/08/03/congress-solaci-sbhci-2023-day-1-summary/" title="Read more" >...</a>

implante de la valvula aortica transcateter

SCOPE I Results at 3 Years: ACURATE Neo vs. SAPIEN 3

Transcatheter aortic valve implantation (TAVI) has become the standard treatment for elderly patients with severe symptomatic aortic stenosis. While this has led to the development of new devices with different features, evidence from randomized studies on these new scaffolds is limited. The randomized SCOPE I study (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared<a href="https://solaci.org/en/2023/07/24/scope-i-results-at-3-years-acurate-neo-vs-sapien-3/" title="Read more" >...</a>

Nueva y discrepante información sobre los vasos no culpables en el infarto

No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study

In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of the worst possible outcomes in terms of left ventricular remodeling, infarct size, ejection fraction and mortality, at long term.&nbsp; The TOTAL study (Routine Aspiration Thrombectomy with PCI Versus<a href="https://solaci.org/en/2023/07/17/no-reflow-after-primary-pci-in-stemi-an-angiographic-analysis-of-the-total-study/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

TAVR Durability at 5 Years in Intermediate Risk Patients

TAVR has been shown beneficial in patients across the risk spectrum. The PARTNER 2 SAPIEN 3 (P2S3i) study on intermediate risk patients was the first to show TAVR superiority vs SAVR when using the transfemoral approach.&nbsp; SAVR durability has been shown in different analysis but, except for a few reports, TAVR durability at long term<a href="https://solaci.org/en/2023/07/11/tavr-durability-at-5-years-in-intermediate-risk-patients/" title="Read more" >...</a>

Relación entre calidad del vaso distal y resultados en tratamiento percutáneo de las oclusiones totales crónicas

Relationship between Distal Vessel Quality and Outcomes in the Treatment of Chronic Total Occlusions

Percutaneous treatment of chronic total occlusions has increase, and has become a a more habitual therapeutic challenge. However, there is limited information on distal vessel quality and its association with outcomes and techniques. This variable appears to be excluded form CTO scores, except for the RECHARGE (REgistry of CrossBoss and Hybrid procedures in FrAnce, the<a href="https://solaci.org/en/2023/07/06/relationship-between-distal-vessel-quality-and-outcomes-in-the-treatment-of-chronic-total-occlusions/" title="Read more" >...</a>

El estudio CULPRIT-SHOCK finalmente se publica en el NEJM y llega para cambiar las guías

Aortic Stenosis and Cardiogenic Shock: Is TAVR an Option?

Cardiogenic shock (CS) in a setting of aortic stenosis is associated with high mortality rates. In consequence, surgery is generally not a possibility for this patient group, and they usually undergo aortic valvuloplasty, resulting in a mortality rate of 33%-50% at 30 days, 70% at one year, and 90% at two years. While transcatheter aortic<a href="https://solaci.org/en/2023/07/04/aortic-stenosis-and-cardiogenic-shock-is-tavr-an-option/" title="Read more" >...</a>

MIL TRAINING MORE MIL: DAY 4 at Favaloro Foundation

&#x25b6; We keep sharing the experience “MIL Train More MIL – SOLACI”, our program on structural heart disease for Latin American Women Interventionists &#x1fa7a; Our scholarship program on structural heart disease continues to thrive in specialized centers in Argentina. &#x1f3e5; Today was Favaloro Foundation’s turn. &#x25b6; Here is the complete scientific program of day 4<a href="https://solaci.org/en/2023/06/30/mil-training-more-mil-day-4-at-favaloro-foundation/" title="Read more" >...</a>

Terapia endovascular en stroke: mucha evidencia y pocos operadores entrenados

VASC-OBSERVANT II Substudy: Impact of Vascular Complications after TAVR

At present, transcatheter aortic valve replacement (TAVR) has become increasingly common to treat severe symptomatic aortic stenosis, with the transfemoral approach being the most common access strategy, associated to better outcomes vs. other access sites. Even though vascular complication rates (VC) have dropped given increased operation experience and improved devices, such as the use of<a href="https://solaci.org/en/2023/06/27/vasc-observant-ii-substudy-impact-of-vascular-complications-after-tavr/" title="Read more" >...</a>

Top